Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors
About this episode
Elena Garralda discusses a new therapy using molecular glue degraders for treating advanced solid tumors at the AACR 2026 meeting.
“Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors” An interview with: Elena Garralda MD PhD, Medical Oncologist, Head, Early Drug Development Unit, Vall d’Hebron Hospital, Barcelona, Spain SAN DIEGO, USA—Cancer cell transcription lies at the heart of a new therapy that has demonstrated potential for treating solid tumors that have become refractory to standard therapy. New data were reported, at the 2026 Annual Meeting of the American Association for Cancer Research, by a group from Spain on the use of a so-called “molecular glue degrader” that modulates transcription to treat cancer. First author Elena Garralda MD PhD, a medical oncologist who leads the Early Drug Development Unit at Vall d’Hebron Hospital in Barcelona, talked about her findings with Peter Goodwin: AUDIO JOURNAL OF ONCOLOGY: Elena Garralda MD PhD IN: [GOODWIN] “I am in San Diego at the …. OUT: ..Audio Journal of Oncoloty, I’m Peter Goodwin” 8:38 secs 2026 AACR Abstract Title CT006 – “Phase 1 DKY709A12101C study in patients with advanced solid tumors treated with DKY709, an IKZF2 degrader, alone or in combination with PDR001, a PD-1…
More episodes of Audio Journal of Oncology Podcast
- Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
- Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
- Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life
- Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy
- Icro Meattini MD; 2026 EBCC: Safe to Avoid Endocrine Therapy in Older Women with Low Risk Breast Cancers: EUROPA Study Interim Findings
- Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Explore listener stats, chart rankings, contacts and more on the Audio Journal of Oncology Podcast podcast page.